메뉴 건너뛰기




Volumn 4, Issue 2, 2018, Pages 173-182

Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC MONOCLONAL ANTIBODY; ATEZOLIZUMAB; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

EID: 85045318992     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.3064     Document Type: Review
Times cited : (806)

References (63)
  • 1
    • 0029947568 scopus 로고    scopus 로고
    • Enhancement of antitumor immunity by CTLA-4 blockade
    • Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736.
    • (1996) Science. , vol.271 , Issue.5256 , pp. 1734-1736
    • Leach, D.R.1    Krummel, M.F.2    Allison, J.P.3
  • 2
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
    • (2012) Nat Rev Cancer. , vol.12 , Issue.4 , pp. 252-264
    • Pardoll, D.M.1
  • 3
    • 0034596948 scopus 로고    scopus 로고
    • Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
    • Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7): 1027-1034.
    • (2000) J Exp Med. , vol.192 , Issue.7 , pp. 1027-1034
    • Freeman, G.J.1    Long, A.J.2    Iwai, Y.3
  • 4
    • 84940403833 scopus 로고    scopus 로고
    • PD-1 blockers
    • Wolchok JD. PD-1 Blockers. Cell. 2015;162(5):937.
    • (2015) Cell , vol.162 , Issue.5 , pp. 937
    • Wolchok, J.D.1
  • 5
    • 0028791059 scopus 로고
    • Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
    • Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(5238): 985-988.
    • (1995) Science. , vol.270 , Issue.5238 , pp. 985-988
    • Waterhouse, P.1    Penninger, J.M.2    Timms, E.3
  • 6
    • 0028867420 scopus 로고
    • Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
    • Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5): 541-547.
    • (1995) Immunity. , vol.3 , Issue.5 , pp. 541-547
    • Tivol, E.A.1    Borriello, F.2    Schweitzer, A.N.3    Lynch, W.P.4    Bluestone, J.A.5    Sharpe, A.H.6
  • 7
    • 0033180181 scopus 로고    scopus 로고
    • Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor
    • Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11 (2):141-151.
    • (1999) Immunity. , vol.11 , Issue.2 , pp. 141-151
    • Nishimura, H.1    Nose, M.2    Hiai, H.3    Minato, N.4    Honjo, T.5
  • 8
    • 0035846991 scopus 로고    scopus 로고
    • Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
    • Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502): 319-322.
    • (2001) Science. , vol.291 , Issue.5502 , pp. 319-322
    • Nishimura, H.1    Okazaki, T.2    Tanaka, Y.3
  • 9
    • 84864052441 scopus 로고    scopus 로고
    • Management of immune-related adverse events and kinetics of response with ipilimumab
    • Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30 (21):2691-2697.
    • (2012) J Clin Oncol. , vol.30 , Issue.21 , pp. 2691-2697
    • Weber, J.S.1    Kähler, K.C.2    Hauschild, A.3
  • 10
    • 85009968823 scopus 로고    scopus 로고
    • Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies
    • Byun DJ,Wolchok JD, Rosenberg LM, GirotraM. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4): 195-207.
    • (2017) Nat Rev Endocrinol. , vol.13 , Issue.4 , pp. 195-207
    • Byun, D.J.1    Wolchok, J.D.2    Rosenberg, L.M.3    Girotra, M.4
  • 11
    • 0022992740 scopus 로고
    • Meta-analysis in clinical trials
    • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
    • (1986) Control Clin Trials. , vol.7 , Issue.3 , pp. 177-188
    • DerSimonian, R.1    Laird, N.2
  • 13
    • 77958110812 scopus 로고    scopus 로고
    • Conductingmeta-analyses in R with the metafor package
    • ViechtbauerW. Conductingmeta-analyses in R with the metafor package. J Stat Softw. 2010;36(3): 1-48.
    • (2010) J Stat Softw. , vol.36 , Issue.3 , pp. 1-48
    • Viechtbauer, W.1
  • 14
    • 84962038946 scopus 로고    scopus 로고
    • Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial
    • (10030)
    • Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387 (10030):1837-1846.
    • (2016) Lancet. , vol.387 , pp. 1837-1846
    • Fehrenbacher, L.1    Spira, A.2    Ballinger, M.3
  • 15
    • 84959577118 scopus 로고    scopus 로고
    • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
    • (10031)
    • Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031): 1909-1920.
    • (2016) Lancet. , vol.387 , pp. 1909-1920
    • Rosenberg, J.E.1    Hoffman-Censits, J.2    Powles, T.3
  • 16
    • 84951126341 scopus 로고    scopus 로고
    • Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer
    • Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34): 4015-4022.
    • (2015) J Clin Oncol. , vol.33 , Issue.34 , pp. 4015-4022
    • Hamanishi, J.1    Mandai, M.2    Ikeda, T.3
  • 17
    • 84964779633 scopus 로고    scopus 로고
    • Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial
    • Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717-726.
    • (2016) Lancet Oncol. , vol.17 , Issue.6 , pp. 717-726
    • Muro, K.1    Chung, H.C.2    Shankaran, V.3
  • 18
    • 84929481481 scopus 로고    scopus 로고
    • Pembrolizumab versus ipilimumab in advanced melanoma
    • Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26): 2521-2532.
    • (2015) N Engl J Med. , vol.372 , Issue.26 , pp. 2521-2532
    • Robert, C.1    Schachter, J.2    Long, G.V.3
  • 19
    • 84936147067 scopus 로고    scopus 로고
    • Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
    • Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
    • (2015) N Engl J Med. , vol.373 , Issue.1 , pp. 23-34
    • Larkin, J.1    Chiarion-Sileni, V.2    Gonzalez, R.3
  • 20
    • 84950117835 scopus 로고    scopus 로고
    • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial
    • (10027)
    • Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027): 1540-1550.
    • (2016) Lancet. , vol.387 , pp. 1540-1550
    • Herbst, R.S.1    Baas, P.2    Kim, D.W.3
  • 21
    • 85016509105 scopus 로고    scopus 로고
    • Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab
    • Weber J, Gibney G, Kudchadkar R, et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. 2016;4(4): 345-353.
    • (2016) Cancer Immunol Res. , vol.4 , Issue.4 , pp. 345-353
    • Weber, J.1    Gibney, G.2    Kudchadkar, R.3
  • 22
    • 84946607195 scopus 로고    scopus 로고
    • Nivolumab versus everolimus in advanced renal-cell carcinoma
    • Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19): 1803-1813.
    • (2015) N Engl J Med. , vol.373 , Issue.19 , pp. 1803-1813
    • Motzer, R.J.1    Escudier, B.2    McDermott, D.F.3
  • 23
    • 84938205998 scopus 로고    scopus 로고
    • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial
    • Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8): 908-918.
    • (2015) Lancet Oncol. , vol.16 , Issue.8 , pp. 908-918
    • Ribas, A.1    Puzanov, I.2    Dummer, R.3
  • 24
    • 84929481480 scopus 로고    scopus 로고
    • Pembrolizumab for the treatment of non-small-cell lung cancer
    • Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372 (21):2018-2028.
    • (2015) N Engl J Med. , vol.372 , Issue.21 , pp. 2018-2028
    • Garon, E.B.1    Rizvi, N.A.2    Hui, R.3
  • 25
    • 84969988424 scopus 로고    scopus 로고
    • Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial
    • Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956-965.
    • (2016) Lancet Oncol. , vol.17 , Issue.7 , pp. 956-965
    • Seiwert, T.Y.1    Burtness, B.2    Mehra, R.3
  • 26
    • 84945554100 scopus 로고    scopus 로고
    • Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
    • Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19): 4286-4293.
    • (2015) Clin Cancer Res. , vol.21 , Issue.19 , pp. 4286-4293
    • Patnaik, A.1    Kang, S.P.2    Rasco, D.3
  • 27
    • 84944937210 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639.
    • (2015) N Engl J Med. , vol.373 , Issue.17 , pp. 1627-1639
    • Borghaei, H.1    Paz-Ares, L.2    Horn, L.3
  • 28
    • 84929572937 scopus 로고    scopus 로고
    • Nivolumab formetastatic renal cell carcinoma: Results of a randomized phase II trial
    • Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab formetastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430-1437.
    • (2015) J Clin Oncol. , vol.33 , Issue.13 , pp. 1430-1437
    • Motzer, R.J.1    Rini, B.I.2    McDermott, D.F.3
  • 29
    • 84983652291 scopus 로고    scopus 로고
    • Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer
    • Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2980-2987.
    • (2016) J Clin Oncol. , vol.34 , Issue.25 , pp. 2980-2987
    • Gettinger, S.1    Rizvi, N.A.2    Chow, L.Q.3
  • 30
    • 84931083080 scopus 로고    scopus 로고
    • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial
    • Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384.
    • (2015) Lancet Oncol. , vol.16 , Issue.4 , pp. 375-384
    • Weber, J.S.1    D'Angelo, S.P.2    Minor, D.3
  • 31
    • 84925222119 scopus 로고    scopus 로고
    • Nivolumab in previously untreated melanoma without BRAF mutation
    • Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4): 320-330.
    • (2015) N Engl J Med. , vol.372 , Issue.4 , pp. 320-330
    • Robert, C.1    Long, G.V.2    Brady, B.3
  • 32
    • 84908354848 scopus 로고    scopus 로고
    • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
    • Robert C, Ribas A,Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109-1117.
    • (2014) Lancet. , vol.384 , Issue.9948 , pp. 1109-1117
    • Robert, C.1    Ribas, A.2    Wolchok, J.D.3
  • 33
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135.
    • (2015) N Engl J Med. , vol.373 , Issue.2 , pp. 123-135
    • Brahmer, J.1    Reckamp, K.L.2    Baas, P.3
  • 34
    • 84978198904 scopus 로고    scopus 로고
    • Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study
    • Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21): 2460-2467.
    • (2016) J Clin Oncol. , vol.34 , Issue.21 , pp. 2460-2467
    • Nanda, R.1    Chow, L.Q.2    Dees, E.C.3
  • 35
    • 84971620553 scopus 로고    scopus 로고
    • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial
    • Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883-895.
    • (2016) Lancet Oncol. , vol.17 , Issue.7 , pp. 883-895
    • Antonia, S.J.1    Lopez-Martin, J.A.2    Bendell, J.3
  • 36
    • 84879777241 scopus 로고    scopus 로고
    • Nivolumab plus ipilimumab in advanced melanoma
    • Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
    • (2013) N Engl J Med. , vol.369 , Issue.2 , pp. 122-133
    • Wolchok, J.D.1    Kluger, H.2    Callahan, M.K.3
  • 37
    • 84924901863 scopus 로고    scopus 로고
    • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial
    • Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3): 257-265.
    • (2015) Lancet Oncol. , vol.16 , Issue.3 , pp. 257-265
    • Rizvi, N.A.1    Mazieres, J.2    Planchard, D.3
  • 38
    • 77954899030 scopus 로고    scopus 로고
    • Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
    • Brahmer JR, Drake CG,Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19): 3167-3175.
    • (2010) J Clin Oncol. , vol.28 , Issue.19 , pp. 3167-3175
    • Brahmer, J.R.1    Drake, C.G.2    Wollner, I.3
  • 39
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26): 2443-2454.
    • (2012) N Engl J Med. , vol.366 , Issue.26 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 40
    • 84976511909 scopus 로고    scopus 로고
    • PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
    • Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26): 2542-2552.
    • (2016) N Engl J Med. , vol.374 , Issue.26 , pp. 2542-2552
    • Nghiem, P.T.1    Bhatia, S.2    Lipson, E.J.3
  • 41
    • 84961827143 scopus 로고    scopus 로고
    • Phase 1 study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    • Shimizu T, Seto T, Hirai F, et al. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest New Drugs. 2016;34 (3):347-354.
    • (2016) Invest New Drugs. , vol.34 , Issue.3 , pp. 347-354
    • Shimizu, T.1    Seto, T.2    Hirai, F.3
  • 42
    • 84929481482 scopus 로고    scopus 로고
    • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
    • PostowMA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21): 2006-2017.
    • (2015) N Engl J Med. , vol.372 , Issue.21 , pp. 2006-2017
    • Postow, M.A.1    Chesney, J.2    Pavlick, A.C.3
  • 43
    • 84944718150 scopus 로고    scopus 로고
    • Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
    • Yamazaki N, Kiyohara Y, Uhara H, et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother Pharmacol. 2015;76(5): 997-1004.
    • (2015) Cancer Chemother Pharmacol. , vol.76 , Issue.5 , pp. 997-1004
    • Yamazaki, N.1    Kiyohara, Y.2    Uhara, H.3
  • 44
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8): 711-723.
    • (2010) N Engl J Med. , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 45
    • 84946558469 scopus 로고    scopus 로고
    • Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes ofmetastatic melanoma
    • Zimmer L, Eigentler TK, Kiecker F, et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes ofmetastatic melanoma. J Transl Med. 2015;13:351.
    • (2015) J Transl Med. , vol.13 , pp. 351
    • Zimmer, L.1    Eigentler, T.K.2    Kiecker, F.3
  • 46
    • 84924543977 scopus 로고    scopus 로고
    • Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma
    • Zimmer L, Vaubel J, Mohr P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One. 2015;10(3):e0118564.
    • (2015) PLoS One. , vol.10 , Issue.3 , pp. e0118564
    • Zimmer, L.1    Vaubel, J.2    Mohr, P.3
  • 47
    • 84883207410 scopus 로고    scopus 로고
    • Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
    • Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382-389.
    • (2013) J Immunother. , vol.36 , Issue.7 , pp. 382-389
    • Le, D.T.1    Lutz, E.2    Uram, J.N.3
  • 48
    • 37349072460 scopus 로고    scopus 로고
    • Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
    • Yang JC, HughesM, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830.
    • (2007) J Immunother. , vol.30 , Issue.8 , pp. 825-830
    • Yang, J.C.1    Hughes, M.2    Kammula, U.3
  • 49
    • 33847407907 scopus 로고    scopus 로고
    • A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy
    • O'Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res. 2007;13(3):958-964.
    • (2007) Clin Cancer Res. , vol.13 , Issue.3 , pp. 958-964
    • O'Mahony, D.1    Morris, J.C.2    Quinn, C.3
  • 50
    • 84876576574 scopus 로고    scopus 로고
    • A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma
    • Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013; 2013:168145.
    • (2013) Sarcoma. , vol.2013 , pp. 168145
    • Maki, R.G.1    Jungbluth, A.A.2    Gnjatic, S.3
  • 51
    • 84961325991 scopus 로고    scopus 로고
    • Risk of endocrine complications in cancer patients treated with immune check point inhibitors: Ameta-analysis
    • Abdel-Rahman O, ElHalawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: ameta-analysis. Future Oncol. 2016;12 (3):413-425.
    • (2016) Future Oncol. , vol.12 , Issue.3 , pp. 413-425
    • Abdel-Rahman, O.1    ElHalawani, H.2    Fouad, M.3
  • 52
    • 85011339270 scopus 로고    scopus 로고
    • Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
    • Morganstein DL, Lai Z, Spain L, et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf). 2017;86(4): 614-620.
    • (2017) Clin Endocrinol (Oxf). , vol.86 , Issue.4 , pp. 614-620
    • Morganstein, D.L.1    Lai, Z.2    Spain, L.3
  • 53
    • 84964910725 scopus 로고    scopus 로고
    • A rare case of thyroid storm
    • bcr-2016-bcr-214603
    • McMillen B, Dhillon MS, Yong-Yow S. A rare case of thyroid storm. BMJ Case Rep. 2016;2016: 1136, bcr-2016-bcr-214603. doi:10.1136/bcr-2016-214603
    • (2016) BMJ Case Rep. , vol.2016 , pp. 1136
    • McMillen, B.1    Dhillon, M.S.2    Yong-Yow, S.3
  • 54
    • 84929347192 scopus 로고    scopus 로고
    • Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies
    • Orlov S, Salari F, Kashat L,Walfish PG. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab. 2015;100(5): 1738-1741.
    • (2015) J Clin Endocrinol Metab. , vol.100 , Issue.5 , pp. 1738-1741
    • Orlov, S.1    Salari, F.2    Kashat, L.3    Walfish, P.G.4
  • 55
    • 84980504294 scopus 로고    scopus 로고
    • Treatment of ipilimumab induced Graves' disease in a patient with metastatic melanoma
    • Azmat U, Liebner D, Joehlin-Price A, Agrawal A, Nabhan F. Treatment of ipilimumab induced Graves' disease in a patient with metastatic melanoma. Case Rep Endocrinol. 2016; 2016:2087525.
    • (2016) Case Rep Endocrinol. , vol.2016 , pp. 2087525
    • Azmat, U.1    Liebner, D.2    Joehlin-Price, A.3    Agrawal, A.4    Nabhan, F.5
  • 56
    • 78751559991 scopus 로고    scopus 로고
    • Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
    • Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011; 164(2):303-307.
    • (2011) Eur J Endocrinol. , vol.164 , Issue.2 , pp. 303-307
    • Min, L.1    Vaidya, A.2    Becker, C.3
  • 57
    • 85022190469 scopus 로고    scopus 로고
    • Clinical features of nivolumab-induced thyroiditis: A case series study
    • Yamauchi I, Sakane Y, Fukuda Y, et al. Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid. 2017;27(7):894-901.
    • (2017) Thyroid. , vol.27 , Issue.7 , pp. 894-901
    • Yamauchi, I.1    Sakane, Y.2    Fukuda, Y.3
  • 58
    • 0038153907 scopus 로고    scopus 로고
    • Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    • Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100(14):8372-8377.
    • (2003) Proc Natl Acad Sci U S A. , vol.100 , Issue.14 , pp. 8372-8377
    • Phan, G.Q.1    Yang, J.C.2    Sherry, R.M.3
  • 59
    • 37349072460 scopus 로고    scopus 로고
    • Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
    • Yang JC, HughesM, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830.
    • (2007) J Immunother. , vol.30 , Issue.8 , pp. 825-830
    • Yang, J.C.1    Hughes, M.2    Kammula, U.3
  • 60
    • 84899071058 scopus 로고    scopus 로고
    • Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody
    • Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45.
    • (2014) Sci Transl Med. , vol.6 , Issue.230 , pp. 230ra45
    • Iwama, S.1    De Remigis, A.2    Callahan, M.K.3    Slovin, S.F.4    Wolchok, J.D.5    Caturegli, P.6
  • 61
    • 84995906230 scopus 로고    scopus 로고
    • Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series
    • Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186(12):3225-3235.
    • (2016) Am J Pathol. , vol.186 , Issue.12 , pp. 3225-3235
    • Caturegli, P.1    Di Dalmazi, G.2    Lombardi, M.3
  • 62
    • 84881186333 scopus 로고    scopus 로고
    • Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma
    • Feng Y, Roy A, Masson E, Chen TT, Humphrey R,Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19(14):3977-3986.
    • (2013) Clin Cancer Res. , vol.19 , Issue.14 , pp. 3977-3986
    • Feng, Y.1    Roy, A.2    Masson, E.3    Chen, T.T.4    Humphrey, R.5    Weber, J.S.6
  • 63
    • 85016813132 scopus 로고    scopus 로고
    • Ipilimumab 10mg/kg versus ipilimumab 3mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial
    • Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10mg/kg versus ipilimumab 3mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5): 611-622.
    • (2017) Lancet Oncol. , vol.18 , Issue.5 , pp. 611-622
    • Ascierto, P.A.1    Del Vecchio, M.2    Robert, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.